Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae469Source: DataRank Database

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection is a research paper published in The Journal of Infectious Diseases (2024). On theSindex it has a DataRank of 0.999. It has been cited 27 times, with 24 citing works in its 1-hop citation network.

N/A

0.999DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access27 citations · 24 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02927067

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 7.92)OA: hybridTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 50%Citation Network 50%

Base Score Contribution

0.500

From this paper's citation signal

Citation Network Contribution

0.499

From 12 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 24 citers.

Emergence of Maribavir‐Resistant Cytomegalovirus in Transplant Recipients Treated for Refractory/Resistant Cytomegalovirus Infection
Journal of Medical Virology20255 citations9 referencesContributes 0.199
CMV infections after HSCT: prophylaxis and treatment
Blood Research20259 citations20 referencesContributes 0.115
Standardizing Care and Management of Cytomegalovirus Infections in Solid Organ Transplant Recipients: Highlights From the Fourth Consensus Guidelines
Transplantation20252 citations11 referencesContributes 0.100
Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients With First Episode or Refractory Cytomegalovirus
CPT Pharmacometrics & Systems Pharmacology20252 citations26 referencesContributes 0.042
A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials
Antiviral Research20251 citations25 referencesContributes 0.028

Authors (13)

Drew J. Winston,Robin K. Avery ORCID,Catherine Cordonnier,Rafael F. Duarte ORCID,Shariq Haider ORCID

Live enrichment

PubMed:39302855 PMC:PMC11911792 OpenAlex:https://openalex.org/W4402666198

NCI NIH HHS

Grant: P30 CA008748

NIH HHS

Grant: R01-AI116635

NIAID NIH HHS

Grant: R01 AI116635

Department of Veterans Affairs

Takeda Development Center Americas, Inc

FWCI

7.92

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://academic.oup.com/jid/article-pdf/231/3/e470/59214416/jiae469.pdf

publisherhttps://academic.oup.com/jid/article-pdf/231/3/e470/59214416/jiae469.pdf

journalhttps://doi.org/10.1093/infdis/jiae469

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39302855

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11911792

Fields of Study

Cytomegalovirus and herpesvirus researchViral-associated cancers and disordersHepatitis B Virus Studies

MeSH Terms

ValganciclovirAdultAgedAntiviral AgentsBenzimidazolesCytomegalovirus InfectionsCytomegalovirusDichlororibofuranosylbenzimidazoleDNA, ViralFemaleHumansMaleMiddle AgedMutationRibonucleosidesGanciclovirTreatment OutcomeHematopoietic Stem Cell TransplantationViral LoadDrug Resistance, ViralYoung Adult

Keywords

GanciclovirValganciclovirDrug resistanceMedicineVirologyFoscarnetCombination therapyInternal medicineCytomegalovirusHuman cytomegalovirusPharmacologyBiologyVirusHerpesviridaeViral diseaseMicrobiologyAntiviral Drug ResistanceAntiviral TherapyMaribavir

Sustainable Development Goals

SDG 0: Good health and well-being